AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- Gambro AB (GAMBa,GAMBb), an international medical technology and health care company, is teaming up with Dendreon Corp. (DNDN) to support the commercialization of Dendreon's therapeutic vaccines. Gambro Healthcare's U.S. network of clinics will serve as cell collection centers and Gambro BCT's COBE Spectra Apheresis System, will be used for the cell collection procedure. The collected cells serve as a raw material component in the production of Dendreon's cancer vaccines.
"We are excited about the opportunity to team with Dendreon and expand our business to serve this new group of patients. These new patient services fit within the strategic direction of Gambro Healthcare, which is focused on providing value-added services that leverage our core competencies and our clinical network," says Larry Buckelew, president of Gambro Healthcare U.S.
David Perez, president of Gambro BCT called Gambro's Spectra apheresis system "the premier device for stem cell collection." The technology, along with the clinical and technical expertise of Gambro BCT and Gambro Healthcare, provides a basis for our therapeutics business strategy: delivering valued blood therapy innovations to improve clinical outcomes for ...
Source: HighBeam Research, Dendreon, Gambro Collaborate On U.S. Cell Collection Network.(Brief...